The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Elin Edda Sigurdardottir; Ingemar Turesson; Sigrun Helga Lund; Ebba K Lindqvist; Sham Mailankody; Neha Korde; Magnus Björkholm; Ola Landgren; Sigurdur Y Kristinsson

doi:10.1001/jamaoncol.2015.23

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Elin Edda Sigurdardottir, Ingemar Turesson, Sigrun Helga Lund, Ebba K Lindqvist, Sham Mailankody, Neha Korde, Magnus Björkholm, Ola Landgren, Sigurdur Y Kristinsson

Avdelningen för hematologi och transfusionsmedicin

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Sammanfattning

Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

Originalspråk	engelska
Sidor (från-till)	168-174
Tidskrift	JAMA Oncology
Volym	1
Nummer	2
DOI	https://doi.org/10.1001/jamaoncol.2015.23
Status	Published - 2015

Ämnesklassifikation (UKÄ)

Cancer och onkologi

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1001/jamaoncol.2015.23

http://www.ncbi.nlm.nih.gov/pubmed/26181017?dopt=Abstract

Citera det här

@article{fd1a312a465044809e3a649fe2248e00,

title = "The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.",

abstract = "Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.",

author = "Sigurdardottir, {Elin Edda} and Ingemar Turesson and Lund, {Sigrun Helga} and Lindqvist, {Ebba K} and Sham Mailankody and Neha Korde and Magnus Bj{\"o}rkholm and Ola Landgren and Kristinsson, {Sigurdur Y}",

year = "2015",

doi = "10.1001/jamaoncol.2015.23",

language = "English",

volume = "1",

pages = "168--174",

journal = "JAMA Oncology",

issn = "2374-2445",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

AU - Sigurdardottir, Elin Edda

AU - Turesson, Ingemar

AU - Lund, Sigrun Helga

AU - Lindqvist, Ebba K

AU - Mailankody, Sham

AU - Korde, Neha

AU - Björkholm, Magnus

AU - Landgren, Ola

AU - Kristinsson, Sigurdur Y

PY - 2015

Y1 - 2015

N2 - Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

AB - Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

U2 - 10.1001/jamaoncol.2015.23

DO - 10.1001/jamaoncol.2015.23

M3 - Article

C2 - 26181017

SN - 2374-2445

VL - 1

SP - 168

EP - 174

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sammanfattning

Ämnesklassifikation (UKÄ)

FN:s Globala mål

Tillgång till dokument

Fingeravtryck

Citera det här